Stephen P.  Ewald net worth and biography

Stephen Ewald Biography and Net Worth

General Counsel of Medpace
Stephen P. Ewald J.D. serves as General Counsel, Corporate Secretary of the Company since June 2012. Mr. Ewald has also led the Human Resources department and other administrative functions since the third quarter of 2017. Prior to joining Medpace, Mr. Ewald served as the Managing Director and Chief Legal Officer of Brevet Capital Management from May 2011 to June 2012. From May 2009 to May 2011, he was a Managing Director and Assistant General Counsel for Cantor Fitzgerald Securities/Cantor Fitzgerald & Co. Mr. Ewald was employed with Bank of America from 1999 to 2009, serving in various roles within the legal department and the Global Markets Group, including Managing Director and Chief Operating Officer of the Principal Capital Group, a proprietary investing group within Bank of America Securities. Mr. Ewald has served as director for several private companies, including as a director and chairman of the board of Mercy Health Foundation Board Cincinnati since 2015 and 2018, respectively, as a director of LIB Therapeutics, LLC since 2015 and as a director of CinRx Pharma, LLC since 2015. Mr. Ewald received his Bachelor of Science in Political Sciences from the University of Cincinnati and his Juris Doctorate from the University of Cincinnati College of Law.

What is Stephen P. Ewald's net worth?

The estimated net worth of Stephen P. Ewald is at least $5.63 million as of July 27th, 2023. Mr. Ewald owns 14,854 shares of Medpace stock worth more than $5,631,746 as of April 18th. This net worth approximation does not reflect any other assets that Mr. Ewald may own. Additionally, Mr. Ewald receives an annual salary of $826,170.00 as General Counsel at Medpace. Learn More about Stephen P. Ewald's net worth.

How old is Stephen P. Ewald?

Mr. Ewald is currently 55 years old. There are 5 older executives and no younger executives at Medpace. The oldest executive at Medpace is Dr. August James Troendle M.D., Chairman & CEO, who is 68 years old. Learn More on Stephen P. Ewald's age.

What is Stephen P. Ewald's salary?

As the General Counsel of Medpace Holdings, Inc., Mr. Ewald earns $826,170.00 per year. There are 3 executives that earn more than Mr. Ewald. The highest earning executive at Medpace is Dr. August James Troendle M.D., Chairman & CEO, who commands a salary of $1,680,000.00 per year. Learn More on Stephen P. Ewald's salary.

How do I contact Stephen P. Ewald?

The corporate mailing address for Mr. Ewald and other Medpace executives is 5375 MEDPACE WAY, CINCINNATI OH, 45227. Medpace can also be reached via phone at (513) 579-9911 and via email at [email protected]. Learn More on Stephen P. Ewald's contact information.

Has Stephen P. Ewald been buying or selling shares of Medpace?

Stephen P. Ewald has not been actively trading shares of Medpace over the course of the past ninety days. Most recently, Stephen P. Ewald sold 21,850 shares of the business's stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $254.39, for a transaction totalling $5,558,421.50. Following the completion of the sale, the general counsel now directly owns 14,854 shares of the company's stock, valued at $3,778,709.06. Learn More on Stephen P. Ewald's trading history.

Who are Medpace's active insiders?

Medpace's insider roster includes Kevin Brady (CFO), Susan Burwig (VP), Stephen Ewald (General Counsel), Jesse Geiger (CFO), Ashley Keating (Director), Tom King (Director), Robert Kraft (Director), and August Troendle (CEO). Learn More on Medpace's active insiders.

Are insiders buying or selling shares of Medpace?

In the last twelve months, insiders at the sold shares 25 times. They sold a total of 841,430 shares worth more than $246,456,813.05. The most recent insider tranaction occured on March, 15th when VP Susan E Burwig sold 102 shares worth more than $41,106.00. Insiders at Medpace own 20.3% of the company. Learn More about insider trades at Medpace.

Information on this page was last updated on 3/15/2024.

Stephen P. Ewald Insider Trading History at Medpace

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/27/2023Sell21,850$254.39$5,558,421.5014,854View SEC Filing Icon  
10/27/2022Sell6,500$220.53$1,433,445.0014,854View SEC Filing Icon  
10/26/2021Sell10,000$209.13$2,091,300.00View SEC Filing Icon  
4/14/2021Sell1,200$180.67$216,804.0015,054View SEC Filing Icon  
2/9/2021Sell10,000$155.48$1,554,800.0023,854View SEC Filing Icon  
12/10/2020Sell10,000$140.07$1,400,700.0023,854View SEC Filing Icon  
8/10/2020Sell7,400$121.57$899,618.0010,736View SEC Filing Icon  
10/18/2019Sell8,000$77.30$618,400.00View SEC Filing Icon  
3/29/2019Sell7,946$57.95$460,470.70View SEC Filing Icon  
See Full Table

Stephen P. Ewald Buying and Selling Activity at Medpace

This chart shows Stephen P Ewald's buying and selling at Medpace by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Medpace Company Overview

Medpace logo
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Read More

Today's Range

Now: $374.32
Low: $373.99
High: $386.24

50 Day Range

MA: $393.75
Low: $318.43
High: $413.31

2 Week Range

Now: $374.32
Low: $185.43
High: $419.42

Volume

219,885 shs

Average Volume

240,621 shs

Market Capitalization

$11.60 billion

P/E Ratio

42.15

Dividend Yield

N/A

Beta

1.38